Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Expected To Encourage Expansion At A CAGR 5.9% from 2014 to 2020 : Grand View Research Inc.
San Francisco, 19 July 2019: The Report Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Analysis By Product (Corticosteroids, Intravenous Immunoglobulin, Anti-D Immunoglobulin, TPO-RA) And Segment Forecasts To 2020
Global idiopathic thrombocytopenic purpura (ITP) therapeutics market is expected to reach USD 566.4 million by 2020. Rising R&D leading to the introduction of new drugs for IVIG and TPO-RA classes is expected to propel growth over the forecast period. In addition, government regulation such as the Orphan Drug Act in the United States with an aim to encourage new product development is projected to fuel growth.
The industry is characterized by rising demand for combination therapies as they exhibit higher efficiency as compared to other treatments. Moreover, they are cost efficient and help curb side effects associated with individual therapeutic classes. Some of the major combination therapies are dexamethasone and rituximab, dexamethasone and TPO-RA, IVIG and corticosteroids. Splenectomy, the procedure to remove spleen is aimed at reducing the amount of anti-platelet antibodies, is expected to fuel demand.
The global market for corticosteroid is valued at over USD 125.0 million in 2013. Corticosteroids are regularly used in idiopathic thrombocytopenic purpura treatment. Since corticosteroid are considered to be the first line of therapy for patients suffering from ITP, the usage rates of corticosteroid are very high.
Access Research Report of Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market @ www.grandviewresearch.com/industry-analysis/idiopathic-thrombocytopenic-purpura-itp-therapeutics
TPO-RA is likely to witness substantial growth, growing at a CAGR of over 9.0% from 2014 to 2020 owing to high response rates exhibited by patients administered with Eltrombopag and Romiplostim. Moreover, demand for TPO-RA is expected to increase due to the commercialization of Avatrombopag in 2015. In addition, the ability of TPO-RA to cater to splenectomized patients witnessing relapses is expected fuel demand over the next six years.
North America accounted for a majority share in 2013 due to rising occurrence of diseases coupled with the presence of high treatment rates, favorable government initiatives, and funding programs. North America had a share of over 40% of the global ITP market by revenue in 2013 and is expected to witness high demand over the forecast period.
Europe accounted for the second largest market share in 2013. This trend is projected to continue over the forecast period due to high usage rates of products along with government initiatives granting of special status to orphan drugs factors.
Asia Pacific is expected to experience substantial growth over the next six years, owing to the presence of favorable government initiatives, and sophisticated healthcare infrastructure in Australia and Japan. In addition, the presence of vast untapped opportunities in emerging markets such as China and India is expected to propel growth.
Some of the major players in the industry are and GlaxoSmithKline Plc., Hoffman-L Roche, Amgen Inc and Grifols Biologicals Inc. The companies make significant R&D investments aimed at new product development by taking advantage of incentives offered under the pertinent government regulations.
Browse more reports of this category by Grand View Research at: www.grandviewresearch.com/industry/pharmaceuticals
Grand View Research has segmented the global ITP therapeutics market on the basis of product and region:
Global ITP Therapeutics Product Outlook (Revenue, USD Million, 2012 - 2020)
About Grand View Research
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.
For More Information: www.grandviewresearch.com
Global idiopathic thrombocytopenic purpura (ITP) therapeutics market is expected to reach USD 566.4 million by 2020. Rising R&D leading to the introduction of new drugs for IVIG and TPO-RA classes is expected to propel growth over the forecast period. In addition, government regulation such as the Orphan Drug Act in the United States with an aim to encourage new product development is projected to fuel growth.
The industry is characterized by rising demand for combination therapies as they exhibit higher efficiency as compared to other treatments. Moreover, they are cost efficient and help curb side effects associated with individual therapeutic classes. Some of the major combination therapies are dexamethasone and rituximab, dexamethasone and TPO-RA, IVIG and corticosteroids. Splenectomy, the procedure to remove spleen is aimed at reducing the amount of anti-platelet antibodies, is expected to fuel demand.
The global market for corticosteroid is valued at over USD 125.0 million in 2013. Corticosteroids are regularly used in idiopathic thrombocytopenic purpura treatment. Since corticosteroid are considered to be the first line of therapy for patients suffering from ITP, the usage rates of corticosteroid are very high.
Access Research Report of Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market @ www.grandviewresearch.com/industry-analysis/idiopathic-thrombocytopenic-purpura-itp-therapeutics
TPO-RA is likely to witness substantial growth, growing at a CAGR of over 9.0% from 2014 to 2020 owing to high response rates exhibited by patients administered with Eltrombopag and Romiplostim. Moreover, demand for TPO-RA is expected to increase due to the commercialization of Avatrombopag in 2015. In addition, the ability of TPO-RA to cater to splenectomized patients witnessing relapses is expected fuel demand over the next six years.
North America accounted for a majority share in 2013 due to rising occurrence of diseases coupled with the presence of high treatment rates, favorable government initiatives, and funding programs. North America had a share of over 40% of the global ITP market by revenue in 2013 and is expected to witness high demand over the forecast period.
Europe accounted for the second largest market share in 2013. This trend is projected to continue over the forecast period due to high usage rates of products along with government initiatives granting of special status to orphan drugs factors.
Asia Pacific is expected to experience substantial growth over the next six years, owing to the presence of favorable government initiatives, and sophisticated healthcare infrastructure in Australia and Japan. In addition, the presence of vast untapped opportunities in emerging markets such as China and India is expected to propel growth.
Some of the major players in the industry are and GlaxoSmithKline Plc., Hoffman-L Roche, Amgen Inc and Grifols Biologicals Inc. The companies make significant R&D investments aimed at new product development by taking advantage of incentives offered under the pertinent government regulations.
Browse more reports of this category by Grand View Research at: www.grandviewresearch.com/industry/pharmaceuticals
Grand View Research has segmented the global ITP therapeutics market on the basis of product and region:
Global ITP Therapeutics Product Outlook (Revenue, USD Million, 2012 - 2020)
- Corticosteroids
- Intravenous Immunoglobulin (IVIG)
- Anti-D Immunoglobulin
- Thrombopoietin Receptor Agonists (TPO-RA)
- Others
- North America
- Europe
- Asia Pacific
- RoW
About Grand View Research
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.
For More Information: www.grandviewresearch.com
Comments
Post a Comment